Brief: Ose Immunotherapeutics Gets EUR 5.2 Mln In Public Funding For Development Of Its 2nd Generation Covid-19 Vaccine

Ose Immunotherapeutics SA

18/12/2020 06:33

Dec 18 (Reuters) - Ose Immunotherapeutics SA  OSE.PA :
    * OSE IMMUNOTHERAPEUTICS RECEIVES €5.2 M IN PUBLIC FUNDING
FOR THE
CLINICAL DEVELOPMENT OF COVEPIT, ITS SECOND GENERATION COVID-19
VACCINE
    * CLINICAL TRIAL EXPECTED TO START IN Q1 2021
    * COVEPIT TARGETS 11 VIRUS PROTEINS TO PREPARE FOR POTENTIAL
MUTATIONS
    * OSE IMMUNOTHERAPEUTICS COMMITTED TO GRANT FRENCH
GOVERNMENT A
PURCHASE OPTION ON DOSES OF COVEPIT VACCINE
    * COVEPIT DEMONSTRATED GENERATION OF SENTINEL MEMORY T CELLS
WITH
LONG-TERM PROTECTIVE EFFECT AGAINST COVID-19 IN PRECLINICAL AND
HUMAN EX VIVO STUDIES

Source text for Eikon:  ID:nBw1QwWdBa 
Further company coverage:  OSE.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))